Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study

Table 2 Severity of illness scores, laboratory tests and use of catecholamines during ICU stay

	New-onset AF, no septic shock (n = 26)	New-onset AF and septic shock (n = 23)	Maintained SR and septic shock (n = 27)	P₁-value	P₂-value
Severity of illness scores
SOFA max	8.5 (4-14)	12 (7-17)	9 (5-18)	< 0.01	0.01
SAPS II	34 (7-60)	31 (15-63)	30 (12-65)	0.87	0.12
Max. CRP level (mg/dl)	249 (14-339)	288 (72-483)	273 (23-412)	0.04	0.28
Use of catecholamines
Noradrenaline max. (μg/kg/min)	0.18 (0.00-1.00)	0.50 (0.15-2.00)	0.30 (0.15-1.40	< 0.01	0.13
Noradrenaline at AF (μg/kg/min)	0.05 (0.00-0.40)	0.40 (0.03-1.10)	-	< 0.01
Dobutamine (number of patients)	2	10	6	< 0.01	0.14
Serum electrolytes at AF
K⁺ (mval/l)	4.4 (3.9-5.0)	4.4 (3.8-5.6)	-	0.63
Na⁺ (mval/l)	137 (130-163)	140 (132-161)	-	0.42
Ca⁺⁺ (mval/l)	1.2 (1.1-1.6)	1.1 (0.7-1.3)	-	0.10

Data are given as median (range in parenthesis) or number. P₁-value, patients with new-onset atrial fibrillation (AF) without septic shock vs. septic shock patients with new-onset AF; P₂-value, septic shock patients with new-onset AF vs. septic shock patients with maintained sinus rhythm (SR).
SOFA max, maximum of the daily calculated sequential organ failure assessment score; SAPS II, simplified acute physiologic score II on admission; Max. CRP level, maximal C-reactive protein level during ICU stay; noradrenaline max, maximal noradrenaline dose during ICU stay; noradrenaline at AF, noradrenaline dose when AF occurred; serum electrolytes at AF, serum electrolyte concentrations when AF occurred.

ISSN: 1364-8535